{"schema_version":"secwatch.filing_event.v1","accession":"0001022079-23-000154","form_type":"8-K","ticker":"DGX","cik":"0001022079","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.912861+00:00","generated_at":"2026-06-09T13:13:09.815121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%","bullets":["Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).","Base business revenue $2.27B (+4.6% YoY); COVID-19 testing revenue $26M (down 92% YoY).","FY2023 guidance: revenue $9.19B-$9.24B, adjusted EPS $8.65-$8.75, raised low end from prior.","Successfully negotiated all strategic health plan renewals for 2023; cites strong physician/hospital channels.","Operating cash flow $207M in Q3 vs $502M year ago; capex $105M."],"urls":{"canonical":"https://secwatch.observer/filing/0001022079-23-000154","json":"https://secwatch.observer/filing/0001022079-23-000154.json","markdown":"https://secwatch.observer/filing/0001022079-23-000154.md","text":"https://secwatch.observer/filing/0001022079-23-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/dgx-20231024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T13:13:09.815121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f43fa24c745f5666204d87f996b879b52533497","claim":"QUEST DIAGNOSTICS INC reported the quarter ended September 30, 2023 results: revenue $2,295, net income $225, EPS $1.96.","evidence_excerpt":"growth.” Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Change 2023 2022 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,295 $ 2,486 (7.7) % $ 6,964 $ 7,550 (7.8) % Base business revenues (a) $ 2,269 $ 2,170 4.6 % $ 6,778 $ 6,280 7.9 % COVID-19 testing revenues $ 26 $ 316 (92.0) % $ 186 $ 1,270 (85.4) %","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$2,295"},{"label":"Net income","value":"$225"},{"label":"EPS","value":"$1.96"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"40907a4b1d21d71ae8ca1d754eced345969c7031","claim":"QUEST DIAGNOSTICS INC updated its Full Year 2023 guidance (reaffirmed).","evidence_excerpt":"The company updates its Full Year 2023 guidance as follows: Updated Guidance Prior Guidance Low High Low High Net revenues $9.19 billion $9.24 billion $9.12 billion $9.22 billion Net revenues decrease (7.0)% (6.5)% (7.7)% (6.7)% Base business revenues (a) $8.99 billion $9.04 billion $8.92 billion $9.02 billion Base business revenues increase 6.7% 7.3% 5.8% 7.0% COVID-19 testing revenues Approximately $200 million Approximately $200 million COVID-19 testing revenues decrease (86.2)% (86.2)% Reported diluted EPS $7.61 $7.71 $7.52 $7.92 Adjusted diluted EPS $8.65 $8.75 $8.50 $8.90 Cash provided by operations Approximately $1.3 billion At least $1.3 billion Capital expenditures Approximately $400 million Approximately $400 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}